VXRT · Vaxart, Inc.
$0.54
-0.02 (-2.95%)
At close · Aug 14
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern for a period of one year from the date of the issuance of these consolidated financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$131.13M
Shares
242.84M
Vaxart, Inc. Earnings Call Transcripts
Every quarterly earnings call for Vaxart, Inc. (VXRT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼100%
$
−$29.31M
'22 Q3
22-11-08
▼70.3%
$22,000
−$23.92M
'22 Q4
23-03-16
▲694.1%
$675,000
−$25.14M
'23 Q1
23-05-09
·
$1.36M
−$22.55M
'23 Q2
23-08-03
·
$2.10M
−$17.40M
'23 Q3
23-11-02
▲14650%
$3.25M
−$17.38M
'23 Q4
24-03-14
▲223.1%
$2.18M
−$24.42M
'24 Q1
24-05-13
▲371.4%
$6.40M
−$16.47M
'24 Q2
24-08-08
▲134.8%
$4.93M
−$14.08M
'24 Q3
24-11-13
▲368%
$15.19M
−$11.98M
'24 Q4
25-03-21
▲857.2%
$20.88M
−$15.59M
'25 Q1
25-05-13
▲520.7%
$39.73M
−$14.99M
'25 Q2
25-08-13
▲1367.9%
$72.41M
−$8.14M
'25 Q3
25-11-13
▲586.5%
$104.24M
$55.05M
'25 Q4
26-03-12
▲87.9%
$39.23M
$5.18M
'26 Q1
26-05-08
LATEST
▼31.6%
$27.18M
−$13.49M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
Vaxart, Inc. Q2 FY2026 Earnings Call
Revenue
$27.18M
▼ 31.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-08
Vaxart, Inc. Q1 FY2026 Earnings Call
Revenue
$39.23M
▲ 87.9% YoY Diluted EPS
$0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Annual General Meeting
Investor event
2026-03-13
Vaxart, Inc. Stockholder Fireside Chat
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-12
Vaxart, Inc. Q4 FY2025 Earnings Call
Positive tone
Phase 2b COVID-19 sentinel cohort data
Dynavax/Sanofi COVID-19 partnership
Oral norovirus vaccine (lactating mothers data)
Revenue
$104.24M*
▲ 586.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Annual General Meeting
Investor event
2025-11-18
Vaxart, Inc. Stockholder Fireside Chat
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-13
Vaxart, Inc. Q3 FY2025 Earnings Call
Confident tone
COVID market opportunity and strain adaptability
Dynavax partnership / business development
Norovirus program and partnership search
Revenue
$72.41M
▲ 1367.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
Vaxart, Inc. Q2 FY2025 Earnings Call
Positive tone
Norovirus program
COVID-19 Phase IIb trial / BARDA stop work order
Partnering and business development
Revenue
$39.73M
▲ 520.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Vaxart, Inc. Q1 FY2025 Earnings Call
Balanced tone
Norovirus vaccine program
COVID-19 Phase 2b trial restart
Reverse stock split and NASDAQ compliance
Revenue
$20.88M
▲ 857.2% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-21
Vaxart, Inc. Q4 FY2024 Earnings Call
Balanced tone
Norovirus Program
COVID-19 Program / Stop Work Order
Government and Regulatory Engagement
Revenue
$15.19M*
▲ 368% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Vaxart, Inc. Q3 FY2024 Earnings Call
Positive tone
Norovirus program
Regulatory engagement with FDA
Early-stage pipeline (HPV, flu, avian flu)
Revenue
$4.93M
▲ 134.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Vaxart, Inc. Q2 FY2024 Earnings Call
Confident tone
BARDA / Project NextGen COVID funding
Norovirus program
Phase 2b COVID oral pill trial
Revenue
$6.40M
▲ 371.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Vaxart, Inc. Q1 FY2024 Earnings Call
Positive tone
Norovirus vaccine in lactating mothers
COVID-19 Phase IIb trial and Project NextGen
New CEO leadership and execution
Revenue
$2.18M
▲ 223.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Vaxart, Inc. Q4 FY2023 Earnings Call
Confident tone
COVID-19 oral vaccine program
Norovirus program
Leadership transition
Revenue
$3.25M*
▲ 14650% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Vaxart, Inc. Q3 FY2023 Earnings Call
Revenue
$2.10M
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Vaxart, Inc. Q2 FY2023 Earnings Call
Revenue
$1.36M
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Vaxart, Inc. Q1 FY2023 Earnings Call
Revenue
$675,000
▲ 694.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Vaxart, Inc. Q4 FY2022 Earnings Call
Revenue
$22,000*
▼ 70.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Vaxart, Inc. Q3 FY2022 Earnings Call
Revenue
$
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Vaxart, Inc. Q2 FY2022 Earnings Call
Revenue
$
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–19 of 19 earnings calls